stoxline Quote Chart Rank Option Currency Glossary
  
Pulse Biosciences, Inc. (PLSE)
17.45  0.63 (3.75%)    07-23 16:00
Open: 16.64
High: 17.49
Volume: 154,125
  
Pre. Close: 16.82
Low: 16.12
Market Cap: 1,068(M)
Technical analysis
2024-07-23 4:54:31 PM
Short term     
Mid term     
Targets 6-month :  23.87 1-year :  27.88
Resists First :  20.43 Second :  23.87
Pivot price 15.77
Supports First :  13.8 Second :  9.69
MAs MA(5) :  16.6 MA(20) :  14.48
MA(100) :  10.41 MA(250) :  8.47
MACD MACD :  1.5 Signal :  1.4
%K %D K(14,3) :  62.4 D(3) :  60.7
RSI RSI(14): 62.9
52-week High :  20.43 Low :  3.77
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PLSE ] has closed below upper band by 33.1%. Bollinger Bands are 136.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.51 - 17.58 17.58 - 17.65
Low: 15.95 - 16.03 16.03 - 16.1
Close: 17.32 - 17.45 17.45 - 17.57
Company Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Headline News

Sat, 20 Jul 2024
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up to $16.38 - American Banking and Market News

Thu, 18 Jul 2024
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up to $16.38 - MarketBeat

Thu, 18 Jul 2024
Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have had a fantastic week as stock increased 10%, and they haven't stopped buying - Simply Wall St

Thu, 18 Jul 2024
Pulse Biosciences (NASDAQ:PLSE) Hits New 1-Year High at $20.44 - Defense World

Wed, 17 Jul 2024
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down to $18.58 - Defense World

Mon, 08 Jul 2024
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 61 (M)
Shares Float 15 (M)
Held by Insiders 72.1 (%)
Held by Institutions 7.9 (%)
Shares Short 2,500 (K)
Shares Short P.Month 2,840 (K)
Stock Financials
EPS -0.8
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.66
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -46.8 %
Return on Equity (ttm) -332.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.71
Qtrly Earnings Growth 0 %
Operating Cash Flow -36 (M)
Levered Free Cash Flow -21 (M)
Stock Valuations
PE Ratio -22.09
PEG Ratio 0
Price to Book value 26.43
Price to Sales 0
Price to Cash Flow -29.48
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android